Singulex, an Alameda, Calif.-based biotech firm, just raised $19 million in fifth-round funding to commercialize technology that uses protein biomarkers to diagnose cardiovascular and other disorders. Already in clinical trials, its system gauges changes in biomarker levels in the bloodstream to give doctors information on the progression and potential management of disease. Singulex has already forged partnerships with several pharmaceutical companies using the system to measure the effects of various drugs during clinical trials.
The recent investment round was led by Jafco Ventures and included OrbiMed Advisors and Fisk Ventures. This brings the company's total capital raised to $50 million since its inception in 2002.